![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, August 24, 2016 10:03:19 PM
This section is where AC5 fits in -
The existing defects of current topical hemostats and the need for further improvements make their use limited to relatively low efficacy conditions, and prevent their application in more extensive situations (5). In fact, at present time, the ideal dressing has not been discovered, and no single hemostatic agent is likely to be superior in every clinical condition. Therefore, there is still the need for the continued refinement of the composition and formation of such dressings. In addition, current hemostats are mostly only available for use in developed countries. These types of products, which can be life-saving in both combat situations and events occurring in everyday life, need to be made available to, or produced in developing parts of the world.
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM